| Autor: |
Dumitru AV; Department of Pathology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pathology, University Emergency Hospital, 050098 Bucharest, Romania., Țăpoi DA; Department of Pathology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pathology, University Emergency Hospital, 050098 Bucharest, Romania., Halcu G; Department of Pathology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pathology, Colțea Clinical Hospital, 030171 Bucharest, Romania., Munteanu O; Department of Anatomy, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Obstetrics and Gynecology, University Emergency Hospital, 050098 Bucharest, Romania., Dumitrascu DI; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania., Ceaușu MC; Department of Pathology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pathology, Alexandru Trestioreanu Institute of Oncology, 022328 Bucharest, Romania., Gheorghișan-Gălățeanu AA; Department of Cellular and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.; C.I. Parhon National Institute of Endocrinology, 011863 Bucharest, Romania. |
| Abstrakt: |
CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, including certain immune cells and cancer ones. This review aims to shed light on the critical importance of CD30, from its emergence in the cell to its position in diagnosing various diseases, including Hodgkin lymphoma, where it is expressed on Hodgkin and Reed-Sternberg cells, as well as embryonal carcinoma, anaplastic large cell lymphoma (ALCL), and cutaneous T-cell lymphoma (CTCL). In addition to its role in positive diagnosis, targeting CD30 has been a promising approach treating CD30-positive lymphomas, and there is ongoing research into the potential use of CD30-targeted therapies for autoimmune disorders. We aim to elaborate on CD30's roles as a tumor marker, supporting thus the hypothesis that this receptor might be the aim of cytostatic treatment. |
